337 related articles for article (PubMed ID: 30027327)
1. MRI Phenotype of RELA-fused Pediatric Supratentorial Ependymoma.
Nowak J; Jünger ST; Huflage H; Seidel C; Hohm A; Vandergrift LA; von Hoff K; Rutkowski S; Pietsch T; Warmuth-Metz M
Clin Neuroradiol; 2019 Dec; 29(4):595-604. PubMed ID: 30027327
[TBL] [Abstract][Full Text] [Related]
2. Supratentorial non-RELA, ZFTA-fused ependymomas: a comprehensive phenotype genotype correlation highlighting the number of zinc fingers in ZFTA-NCOA1/2 fusions.
Tauziède-Espariat A; Siegfried A; Nicaise Y; Kergrohen T; Sievers P; Vasiljevic A; Roux A; Dezamis E; Benevello C; Machet MC; Michalak S; Puiseux C; Llamas-Gutierrez F; Leblond P; Bourdeaut F; Grill J; Dufour C; Guerrini-Rousseau L; Abbou S; Dangouloff-Ros V; Boddaert N; Saffroy R; Hasty L; Wahler E; Pagès M; Andreiuolo F; Lechapt E; Chrétien F; Blauwblomme T; Beccaria K; Pallud J; Puget S; Uro-Coste E; Varlet P;
Acta Neuropathol Commun; 2021 Aug; 9(1):135. PubMed ID: 34389065
[TBL] [Abstract][Full Text] [Related]
3. Diagnostics of pediatric supratentorial RELA ependymomas: integration of information from histopathology, genetics, DNA methylation and imaging.
Pagès M; Pajtler KW; Puget S; Castel D; Boddaert N; Tauziède-Espariat A; Picot S; Debily MA; Kool M; Capper D; Sainte-Rose C; Chrétien F; Pfister SM; Pietsch T; Grill J; Varlet P; Andreiuolo F
Brain Pathol; 2019 May; 29(3):325-335. PubMed ID: 30325077
[TBL] [Abstract][Full Text] [Related]
4. Specific expression of PD-L1 in RELA-fusion supratentorial ependymoma: Implications for PD-1-targeted therapy.
Witt DA; Donson AM; Amani V; Moreira DC; Sanford B; Hoffman LM; Handler MH; Levy JMM; Jones KL; Nellan A; Foreman NK; Griesinger AM
Pediatr Blood Cancer; 2018 May; 65(5):e26960. PubMed ID: 29350470
[TBL] [Abstract][Full Text] [Related]
5. A novel type of C11orf95-LOC-RELA fusion in a grade II supratentorial ependymoma: report of a case with literature review.
de Sousa GR; Marie SKN; Oba-Shinjo SM; Ramalho LNZ; Tone LG; Valera ET
Childs Nerv Syst; 2019 Apr; 35(4):689-694. PubMed ID: 30631904
[TBL] [Abstract][Full Text] [Related]
6. Significance of molecular classification of ependymomas: C11orf95-RELA fusion-negative supratentorial ependymomas are a heterogeneous group of tumors.
Fukuoka K; Kanemura Y; Shofuda T; Fukushima S; Yamashita S; Narushima D; Kato M; Honda-Kitahara M; Ichikawa H; Kohno T; Sasaki A; Hirato J; Hirose T; Komori T; Satomi K; Yoshida A; Yamasaki K; Nakano Y; Takada A; Nakamura T; Takami H; Matsushita Y; Suzuki T; Nakamura H; Makino K; Sonoda Y; Saito R; Tominaga T; Matsusaka Y; Kobayashi K; Nagane M; Furuta T; Nakada M; Narita Y; Hirose Y; Ohba S; Wada A; Shimizu K; Kurozumi K; Date I; Fukai J; Miyairi Y; Kagawa N; Kawamura A; Yoshida M; Nishida N; Wataya T; Yamaoka M; Tsuyuguchi N; Uda T; Takahashi M; Nakano Y; Akai T; Izumoto S; Nonaka M; Yoshifuji K; Kodama Y; Mano M; Ozawa T; Ramaswamy V; Taylor MD; Ushijima T; Shibui S; Yamasaki M; Arai H; Sakamoto H; Nishikawa R; Ichimura K;
Acta Neuropathol Commun; 2018 Dec; 6(1):134. PubMed ID: 30514397
[TBL] [Abstract][Full Text] [Related]
7. L1CAM Immunopositivity in Anaplastic Supratentorial Ependymomas: Correlation With Clinical and Histological Parameters.
Chavali P; Rao S; Palavalasa S; Bevinahalli N; Muthane YTC; Sadashiva N; Santosh V
Int J Surg Pathol; 2019 May; 27(3):251-258. PubMed ID: 30251576
[TBL] [Abstract][Full Text] [Related]
8. Supratentorial ependymoma in childhood: more than just RELA or YAP.
Zschernack V; Jünger ST; Mynarek M; Rutkowski S; Garre ML; Ebinger M; Neu M; Faber J; Erdlenbruch B; Claviez A; Bielack S; Brozou T; Frühwald MC; Dörner E; Dreschmann V; Stock A; Solymosi L; Hench J; Frank S; Vokuhl C; Waha A; Andreiuolo F; Pietsch T
Acta Neuropathol; 2021 Mar; 141(3):455-466. PubMed ID: 33481105
[TBL] [Abstract][Full Text] [Related]
9. C11orf95-RELA fusions and upregulated NF-KB signalling characterise a subset of aggressive supratentorial ependymomas that express L1CAM and nestin.
Malgulwar PB; Nambirajan A; Pathak P; Faruq M; Rajeshwari M; Singh M; Suri V; Sarkar C; Sharma MC
J Neurooncol; 2018 May; 138(1):29-39. PubMed ID: 29354850
[TBL] [Abstract][Full Text] [Related]
10. Role of Immunohistochemistry in the Identification of Supratentorial C11ORF95-RELA Fused Ependymoma in Routine Neuropathology.
Gessi M; Giagnacovo M; Modena P; Elefante G; Gianno F; Buttarelli FR; Arcella A; Donofrio V; Diomedi Camassei F; Nozza P; Morra I; Massimino M; Pollo B; Giangaspero F; Antonelli M
Am J Surg Pathol; 2019 Jan; 43(1):56-63. PubMed ID: 29266023
[TBL] [Abstract][Full Text] [Related]
11. C11orf95-RELA reprograms 3D epigenome in supratentorial ependymoma.
Zhu JJ; Jillette N; Li XN; Cheng AW; Lau CC
Acta Neuropathol; 2020 Dec; 140(6):951-960. PubMed ID: 32909151
[TBL] [Abstract][Full Text] [Related]
12. Notch pathway in ependymoma RELA-fused subgroup: upregulation and association with cancer stem cells markers expression.
de Almeida Magalhães T; Cruzeiro GAV; de Sousa GR; da Silva KR; Lira RCP; Scrideli CA; Tone LG; Valera ET; Borges KS
Cancer Gene Ther; 2020 Jun; 27(6):509-512. PubMed ID: 31308481
[TBL] [Abstract][Full Text] [Related]
13. Characterization of molecular signatures of supratentorial ependymomas.
Torre M; Alexandrescu S; Dubuc AM; Ligon AH; Hornick JL; Meredith DM
Mod Pathol; 2020 Jan; 33(1):47-56. PubMed ID: 31375768
[TBL] [Abstract][Full Text] [Related]
14. Ependymoma-like tumor with mesenchymal differentiation harboring C11orf95-NCOA1/2 or -RELA fusion: A hitherto unclassified tumor related to ependymoma.
Tomomasa R; Arai Y; Kawabata-Iwakawa R; Fukuoka K; Nakano Y; Hama N; Nakata S; Suzuki N; Ishi Y; Tanaka S; Takahashi JA; Yuba Y; Shiota M; Natsume A; Kurimoto M; Shiba Y; Aoki M; Nabeshima K; Enomoto T; Inoue T; Fujimura J; Kondo A; Yao T; Okura N; Hirose T; Sasaki A; Nishiyama M; Ichimura K; Shibata T; Hirato J; Yokoo H; Nobusawa S
Brain Pathol; 2021 May; 31(3):e12943. PubMed ID: 33576087
[TBL] [Abstract][Full Text] [Related]
15. epi-Aszonalenin B from Aspergillus novofumigatus inhibits NF-κB activity induced by ZFTA-RELA fusion protein that drives ependymoma.
Ishikawa K; Ishii M; Yaguchi T; Katada T; Ichinose K; Ohata S
Biochem Biophys Res Commun; 2022 Mar; 596():104-110. PubMed ID: 35131506
[TBL] [Abstract][Full Text] [Related]
16. C11orf95-RELA fusion present in a primary supratentorial ependymoma and recurrent sarcoma.
Cachia D; Wani K; Penas-Prado M; Olar A; McCutcheon IE; Benjamin RS; Armstrong TS; Gilbert MR; Aldape KD
Brain Tumor Pathol; 2015 Apr; 32(2):105-11. PubMed ID: 25388523
[TBL] [Abstract][Full Text] [Related]
17. CDKN2A deletion in supratentorial ependymoma with RELA alteration indicates a dismal prognosis: a retrospective analysis of the HIT ependymoma trial cohort.
Jünger ST; Andreiuolo F; Mynarek M; Wohlers I; Rahmann S; Klein-Hitpass L; Dörner E; Zur Mühlen A; Velez-Char N; von Hoff K; Warmuth-Metz M; Kortmann RD; Timmermann B; von Bueren A; Rutkowski S; Pietsch T
Acta Neuropathol; 2020 Sep; 140(3):405-407. PubMed ID: 32514758
[No Abstract] [Full Text] [Related]
18. C11orf95-RELA fusion drives aberrant gene expression through the unique epigenetic regulation for ependymoma formation.
Ozawa T; Kaneko S; Szulzewsky F; Qiao Z; Takadera M; Narita Y; Kondo T; Holland EC; Hamamoto R; Ichimura K
Acta Neuropathol Commun; 2021 Mar; 9(1):36. PubMed ID: 33685520
[TBL] [Abstract][Full Text] [Related]
19. Molecular subgrouping of ependymoma across three anatomic sites and their prognostic implications.
Chinnam D; Gupta K; Kiran T; Saraswati A; Salunke P; Madan R; Kumar N; Radotra BD
Brain Tumor Pathol; 2022 Jul; 39(3):151-161. PubMed ID: 35348910
[TBL] [Abstract][Full Text] [Related]
20. Review of ependymomas: assessment of consensus in pathological diagnosis and correlations with genetic profiles and outcome.
Sasaki A; Hirato J; Hirose T; Fukuoka K; Kanemura Y; Hashimoto N; Kodama Y; Ichimura K; Sakamoto H; Nishikawa R
Brain Tumor Pathol; 2019 Apr; 36(2):92-101. PubMed ID: 30929114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
